Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Inclusion Criteria: * Histologically or cytologically confirmed cholangiocarcinoma. * Radiographically measurable or evaluable disease per RECIST v1.1. * Tumor assessment for FGF/FGFR gene alteration status. * Documented disease progression after at least 1 line of prior systemic therapy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Life expectancy ≥ 12 weeks. Exclusion Criteria: * Prior receipt of a selective FGFR inhibitor. * History of and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications. * Current evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination. * Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.